Moderna advances multiple vaccine programs to late-stage clinical trials

Announces next-generation covid-19 vaccine candidate as fourth respiratory vaccine to successfully meet its phase 3 endpoints expects two more phase 3 readouts in 2024, including combination vaccine against flu and covid-19, and vaccine against cmv announces positive clinical trial data from three new vaccines against viruses that cause significant burden (epstein-barr virus, varicella-zoster virus, norovirus) and advances programs toward phase 3 development anticipates u.s. launch of vaccine against rsv following fda approval and acip recommendation in 2024 announces development and commercialization funding agreement with blackstone life sciences for up to $750 million to advance flu program cambridge, ma / accesswire / march 27, 2024 / moderna, inc. (nasdaq:mrna) today announced at its fifth vaccines day event clinical and program updates demonstrating advancement and acceleration of its mrna pipeline. the updates include data readouts in the company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business.
MRNA Ratings Summary
MRNA Quant Ranking